Anavex to Present at Upcoming Rodman & Renshaw Annual Global Investment Conference in New York

New York, NY — September 3, 2013 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL) today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will be presenting at the Rodman & Renshaw Annual Global Investment Conference on Monday, September 9, 2013 at 3:15 p.m. ET in Room 7.03 of the…

Anavex to Present at Upcoming Rodman & Renshaw Annual Global Investment Conference in New York

New York, NY — September 3, 2013 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL) today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will be presenting at the Rodman & Renshaw Annual Global Investment Conference on Monday, September 9, 2013 at 3:15 p.m. ET in Room 7.03 of the…

Anavex Raises $2.6-Million in Private Placement and Conversion of Liabilities, Enters Into $10-Million Financing Commitment and Appoints CEO

New York, NY — July 8, 2013 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL) today announced the closing of $2.6-million in a private placement financing and conversion of liabilities and an agreement with institutional investor Lincoln Park Capital Fund, LLC (“Lincoln Park Capital”) for a funding commitment of up to $10-million…

ANAVEX 2-73 Restores Mitochondrial Functionality, Blocks Cell Death and Oxidative Stress, Preventing Onset of Alzheimer’s Disease

New data presented at International Conference on Alzheimer’s and Parkinson’s Diseases Vancouver, BC — March 12, 2013 — Anavex Life Sciences Corp. (“Anavex”) (OTCQB: AVXL) today announced more promising new data for ANAVEX 2-73, the company’s lead drug candidate for Alzheimer’s disease. In a scientific study conducted in France at the University of Montpellier and…

Anavex Retains Novak Druce Connolly Bove & Quigg to Maximize Value of Intellectual Property Portfolio

Vancouver, BC — February 4, 2013 — Anavex Life Sciences Corp. (“Anavex”) (OTCQB: AVXL) is pleased to announce that it has retained specialized intellectual property law firm Novak Druce Connolly Bove & Quigg LLP (“Novak Druce”) to assist in maximizing the value of the company’s intellectual property (IP) portfolio.  One of the largest IP boutique…

ANAVEX 2-73 Shown to Block Oxidative Stress, Preventing Onset of Alzheimer’s Disease

Data presented at Neuroscience 2012 Vancouver, BC — October 18, 2012 — Anavex Life Sciences Corp. (“Anavex”) (OTCQB: AVXL) today unveiled more promising new data regarding ANAVEX 2-73, the company’s drug candidate for the treatment and modification of Alzheimer’s disease currently in human clinical trials. The confidential status of the new ANAVEX 2-73 data has been…